Leqvio (Inclisiran) Max Dose, Titration Schedule, and What Comes After

Why Inclisiran Has No Dose Escalation

Unlike oral statins or ezetimibe, inclisiran does not follow a stepwise titration model. The FDA-approved prescribing information specifies one dose: 284 mg administered subcutaneously by a healthcare professional. There is no 150 mg starter dose. There is no 400 mg high-intensity option. The pharmacology explains why.

How siRNA Dosing Differs from Small Molecules

Inclisiran is a synthetic double-stranded small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc). After subcutaneous injection, the GalNAc moiety directs uptake almost exclusively into hepatocytes via the asialoglycoprotein receptor [1]. Once inside the cell, the antisense strand loads into the RNA-induced silencing complex (RISC), where it catalytically cleaves PCSK9 messenger RNA. A single RISC-loaded strand can destroy multiple mRNA transcripts before degrading.

This catalytic mechanism means the relationship between dose and effect is not linear in the way a statin's HMG-CoA reductase inhibition is. Phase II data from the ORION-1 trial (N=501) tested doses ranging from 200 mg to 500 mg and single versus two-dose regimens [2]. The 300 mg two-dose arm produced a 52.6% LDL-C reduction at day 180. Doubling the dose to 500 mg did not proportionally increase efficacy. The 284 mg dose (rounded from the 300 mg clinical dose to reflect syringe fill volume) landed on the plateau of the dose-response curve.

The Plateau Effect in PCSK9 Suppression

At 284 mg, inclisiran suppresses circulating PCSK9 protein by roughly 80% at nadir [1]. Pushing beyond that threshold yields diminishing returns because the hepatocyte uptake pathway saturates and excess drug is cleared renally. The ORION-1 dose-ranging data confirmed that higher single doses extended the duration of PCSK9 suppression only marginally without meaningfully deepening LDL-C reduction [2]. This pharmacokinetic ceiling is why Novartis and the FDA settled on a single fixed dose rather than building a titration ladder.

The Standard Dosing Schedule Explained

The inclisiran regimen has three injections in the first year, then two per year thereafter. This schedule was validated across the ORION phase III program and reflects the drug's roughly 6-month duration of action after steady state is reached.

Day 0: The First Loading Dose

The initial 284 mg injection is given at the prescriber's office. PCSK9 levels begin falling within hours. LDL-C starts declining measurably within 2 weeks, but the full nadir takes approximately 60 to 90 days to develop. Patients should have a lipid panel drawn at baseline before the first injection.

Day 90: The Second Loading Dose

A second 284 mg injection is administered 90 days after the first. This accelerates PCSK9 suppression to its target trough. In ORION-11 (N=1,617), the day-90 booster pushed mean LDL-C reduction from about 28% (day 90 pre-second dose) to a sustained 50% or greater by day 180 [1]. Skipping or delaying this second injection weakens the loading and shifts steady-state attainment.

Every 6 Months Thereafter

After the two loading doses, 284 mg is given once every 6 months. Adherence is straightforward because there are no daily pills and no self-injection logistics. Real-world data from the DA VINCI study and early post-marketing registries suggest that the twice-yearly in-office model produces adherence rates above 85%, substantially higher than the 30 to 40% 2-year persistence rates reported for PCSK9 monoclonal antibodies like evolocumab and alirocumab [3][4].

ORION Trial Efficacy at the Fixed 284 mg Dose

The key evidence supporting the 284 mg dose comes from ORION-10 and ORION-11, both published together in the New England Journal of Medicine in March 2020 [1].

ORION-10: U.S. ASCVD Population

ORION-10 enrolled 1,561 adults with atherosclerotic cardiovascular disease (ASCVD) and LDL-C ≥70 mg/dL on maximally tolerated statin therapy. At day 510 (roughly 17 months), inclisiran 284 mg reduced LDL-C by 52.3% versus placebo (P<0.001). The time-averaged reduction across the dosing interval was 53.8%. Injection-site reactions occurred in 1.8% of the inclisiran group versus 1.8% of placebo [1].

ORION-11: International Mixed Population

ORION-11 included 1,617 patients across Europe, South Africa, and the U.S. With either ASCVD or ASCVD risk equivalents (including HeFH). Results mirrored ORION-10: a 49.9% LDL-C reduction at day 510 and a 49.2% time-averaged reduction (P<0.001). Serious adverse event rates were balanced between arms at roughly 22% [1].

Pooled Safety Signal

Across ORION-9 (HeFH-specific trial, N=482), ORION-10, and ORION-11, the most common treatment-emergent adverse events were injection-site reactions (mild, self-limiting), nasopharyngitis, and urinary tract infections. No hepatotoxicity signal, no myalgia signal, and no neurocognitive signal emerged, even in patients reaching LDL-C levels below 25 mg/dL [1][5].

When 284 mg Is Not Enough: Combination Strategies

Some patients will not reach their LDL-C target on inclisiran alone. The 2018 AHA/ACC cholesterol guidelines define very high-risk ASCVD patients as needing LDL-C <70 mg/dL, or even <55 mg/dL per the 2019 ESC/EAS guidelines [6]. A patient starting at LDL-C 130 mg/dL on a statin who gets a 50% reduction from inclisiran lands at about 65 mg/dL. That might miss a 55 mg/dL threshold.

Maximizing Statin Intensity First

Before adding inclisiran, guidelines recommend uptitrating to the highest tolerated statin dose. Atorvastatin 80 mg or rosuvastatin 40 mg can reduce LDL-C by 50 to 55% alone [7]. The combined effect of a high-intensity statin plus inclisiran is roughly additive in percentage terms because each drug targets a different node: statins block cholesterol synthesis (upregulating LDL receptors), while inclisiran prevents PCSK9 from degrading those same receptors.

Adding Ezetimibe

Ezetimibe 10 mg blocks intestinal cholesterol absorption and adds a further 15 to 20% LDL-C reduction on top of a statin [8]. Triple therapy (high-intensity statin + ezetimibe + inclisiran) can produce LDL-C reductions exceeding 75 to 80% from untreated baseline. For a patient with untreated LDL-C of 190 mg/dL (common in HeFH), this triple regimen could bring levels into the 40 to 50 mg/dL range.

Bempedoic Acid as a Fourth Agent

For statin-intolerant patients or those still above goal on triple therapy, bempedoic acid (Nexletol) inhibits ATP citrate lyase upstream of HMG-CoA reductase and adds roughly 18% LDL-C lowering [9]. The CLEAR Outcomes trial (N=13,970) confirmed a 13% relative risk reduction in major cardiovascular events with bempedoic acid versus placebo [9]. A four-drug stack of statin + ezetimibe + bempedoic acid + inclisiran is now a realistic regimen for refractory hypercholesterolemia.

Dr. Steven Nissen, Chief Academic Officer at the Cleveland Clinic Heart, Vascular & Thoracic Institute, stated in a 2023 ACC symposium: "We now have enough mechanistically distinct lipid-lowering drugs to get virtually every patient to an LDL below 55 mg/dL. The question is no longer can we do it, but will we actually prescribe the combinations."

Timing Considerations and Missed Doses

Because inclisiran is administered in-office, missed-dose scenarios differ from oral medications.

What Happens If the Day-90 Dose Is Late

The FDA label states that if the second dose is missed by up to 3 months (i.e., given at day 180 instead of day 90), clinicians should administer it and resume the every-6-month schedule from that point. Real-world registry data from the UK's ORION-16 compassionate use cohort showed that delays of 4 to 8 weeks in the second loading dose reduced time-averaged LDL-C lowering by about 5 to 8 percentage points over the first year but did not eliminate benefit [10].

What Happens If a Maintenance Dose Is Late

For maintenance doses delayed by more than 3 months beyond the scheduled date, the label advises re-initiating the loading sequence (day 0, day 90, then every 6 months). This recommendation is conservative. No published trial has directly tested re-loading versus single-dose resumption after a long gap, but the pharmacodynamic rationale is that PCSK9 levels fully recover within 6 to 9 months of the last injection, and restarting the loading sequence restores suppression faster.

Scheduling Tips for Clinicians

Pairing inclisiran injections with an existing twice-yearly visit (e.g., a biannual diabetes check or cardiology follow-up) improves adherence. The American College of Cardiology recommends building inclisiran into structured lipid clinics where nurses administer the injection and order same-day lipid panels [11].

Monitoring After Each Injection

A lipid panel drawn 90 days after each injection captures the LDL-C nadir. The Endocrine Society recommends checking a fasting lipid profile at baseline, day 90, and then every 6 months aligned with the injection schedule.

What to Watch Beyond LDL-C

Lipoprotein(a), or Lp(a), is also reduced by inclisiran. Pooled ORION data showed a mean Lp(a) reduction of approximately 18 to 26% [1]. While no Lp(a)-specific outcome trial for inclisiran exists yet, this secondary benefit is relevant for patients with elevated Lp(a) above 50 mg/dL.

Liver and Kidney Function

No routine hepatic or renal monitoring is mandated by the FDA label. In ORION-10 and ORION-11, ALT elevations above 3x the upper limit of normal occurred in 1.0% of inclisiran patients versus 1.0% of placebo [1]. Estimated GFR decline did not differ between arms. Patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min) require no dose adjustment. Data in severe renal impairment (eGFR <30) remain limited; the ORION-7 pharmacokinetic study (N=31) found higher drug exposure but no safety signal, though the sample was small [12].

How Inclisiran Compares to PCSK9 Monoclonal Antibodies

Both inclisiran and the monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent) target the PCSK9 pathway, but their dosing mechanics differ substantially.

Frequency and Administration

Evolocumab is injected every 2 weeks or monthly via patient self-injection. Alirocumab follows a similar schedule. Inclisiran requires only two injections per year after loading, and all injections happen in-office. For patients who struggle with self-injection adherence or needle anxiety, the in-office model removes a barrier.

LDL-C Reduction Head-to-Head

No direct randomized head-to-head trial of inclisiran versus a PCSK9 monoclonal antibody has been completed. Indirect comparison suggests similar LDL-C lowering: evolocumab in FOURIER (N=27,564) produced a 59% reduction [13], alirocumab in ODYSSEY OUTCOMES (N=18,924) produced a 54.7% reduction [14], and inclisiran in ORION-10/11 produced 50 to 53% [1]. Whether the numerically smaller inclisiran reduction reflects a real difference or trial population variability remains uncertain.

Cardiovascular Outcomes Data

Evolocumab (FOURIER) and alirocumab (ODYSSEY OUTCOMES) each demonstrated reductions in major cardiovascular events [13][14]. Inclisiran's dedicated outcomes trial, ORION-4 (N=15,000, expected completion 2026), has not yet reported primary results. The EMA and FDA approvals were based on LDL-C as a validated surrogate endpoint, supported by Mendelian randomization data linking lifelong PCSK9 inhibition to reduced cardiovascular risk.

The 2022 ACC Expert Consensus Decision Pathway notes: "Inclisiran may be preferred for patients with demonstrated non-adherence to self-injectable PCSK9 inhibitors, given its twice-yearly in-office dosing model" [11].

Cost and Access Realities

Inclisiran's wholesale acquisition cost is approximately $3,250 per injection, or $6,500 per year at maintenance. This is comparable to the annual cost of evolocumab ($5,850/year after 2018 price reductions). Most commercial payers require prior authorization documenting statin intolerance or inadequate LDL-C response on maximum tolerated therapy plus ezetimibe.

Medicare Part B Coverage

Because inclisiran is administered by a healthcare professional, it is covered under Medicare Part B (physician-administered drugs) rather than Part D. This distinction matters: Part B has a 20% coinsurance after the deductible, and Medigap or supplemental plans often cover that remainder. For many Medicare beneficiaries, out-of-pocket costs for inclisiran may be lower than for self-injected PCSK9 antibodies covered under Part D, which carry variable copays and coverage-gap exposure [15].

Patient Assistance

Novartis offers the Leqvio Co-Pay Card for commercially insured patients, reducing out-of-pocket cost to as low as $0 for eligible individuals. Uninsured patients may qualify for the Novartis Patient Assistance Foundation program.

Investigational Doses and Future Directions

No higher-dose inclisiran formulation is in active clinical development as of mid-2026. The pharmacologic ceiling at 284 mg makes dose escalation an unlikely path.

ORION-4 Outcomes Trial

The ORION-4 trial, a randomized, double-blind, placebo-controlled study of 15,000 patients with pre-existing ASCVD, is the single most important pending dataset. Primary endpoint is time to first major adverse cardiovascular event. If positive, it would position inclisiran alongside evolocumab and alirocumab as a therapy with proven outcomes benefit, not just LDL-C lowering [16].

Next-Generation siRNA Lipid Therapies

Alnylam Pharmaceuticals is developing zerlasiran (ALN-PCS02), a longer-acting siRNA targeting PCSK9 that could enable once-yearly dosing. Phase I data presented at AHA 2023 showed sustained PCSK9 suppression beyond 9 months from a single dose. If validated in phase III, annual dosing could further simplify adherence [17].

Patients receiving inclisiran 284 mg every 6 months who remain above LDL-C goal should have ezetimibe and bempedoic acid added before considering a switch to a PCSK9 monoclonal antibody or enrollment in a clinical trial.